Dr. Medhavi Jogi's Credentials
Accepting New Patients
Yes, this doctor is accepting new patients
Dr. Jogi is a true native Texan, having been born in Austin and attending the University of Texas for his undergraduate education. He completed his medical training at the prestigious Baylor College of Medicine in Houston spending the last several years of training actively involved in academic research, publishing several well-received papers and a textbook chapter as well as winning numerous academic awards. His current interests include general endocrinology and managing all forms of thyroid disease by offering the newest techniques and using up-to-date research which was developed while training at the world-renowned MD Anderson Hospital. He also has specialty training in the management of diseases of the pituitary, pancreas, bone, ovaries/gonads as well as adrenal glands. He is double board certified and an active member of numerous national endocrinology societies including the American Thyroid Association, American College of Clinical Endocrinologists, Texas Medical Association, Harris County Medical Society and the American College of Physicians. Dr. Jogi also is involved in several other medical ventures. He is the chief medical officer for PrescribeWell, an online physician-centric health management system. He is also the medical editor of the website HoustonEndocrine.com. He spends his time taking care of his children and his wife, a successful Houston dermatologist. He is well-recognized by his patients for having a amiable disposition and a warm bed-side manner which is most noticeable in the care he takes to explain every aspect of their disease and treatment.
- Baylor College Of Medicine (Grad. 2002)
Areas of Expertise
- Hyperthyroidism (overactive thyroid)
- Hypothyroidism (underactive thyroid)
- Thyroid nodules
- Postpartum thyroiditis
- Thyroid cancer
- Graves' disease
- Hashimoto's disease
- Type 1 diabetes
- Type 2 diabetes
Awards & Recognitions
Publications & Research
- Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
- Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
- False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH.